Investment Team

  • Michael Dial, PhD


    Michael Dial, PhD

    Mike joined Hatteras in 2009 from Silicon Valley Bank, where he was a Vice President in the Corporate Finance Group focused on emerging tech and life science companies and venture capital funds. Prior to SVB, he held research scientist positions in the Department of Biochemistry at UNC-Chapel Hill, the Laboratory of Structural Biology at the National Institute of Environmental Health Sciences, and the UNC-Duke Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics, and cancer therapy.

    Mike is a Professor of the Practice at the Kenan-Flagler Business School at The University of North Carolina at Chapel Hill and is also the Manager of the Carolina Research Ventures Fund, a fund dedicated to UNC-Chapel Hill related start-ups. He holds a Ph.D. in Biochemistry and Biophysics from UNC-Chapel Hill.

    Community and Board Engagements:

    Mike serves on the boards of Genturi and StrideBio and is a board observer at Spyryx. Previously, Mike was involved with G1 Therapeutics, Viamet, Lysosomal Therapeutics, Artizan Biosciences and Curoverse, among others, and has held various operational roles in portfolio companies. Mike has also served on committees and panels for the North Carolina Biotech Center, Council for Entrepreneurial Development, SEBIO, and PTP NEXT.

  • Jeff Terrell


    Jeff Terrell

    Prior to joining the Hatteras team in 2012, Jeff worked in a sales and clinical support role for a large Medtronic distributor. Based in Georgia and South Carolina, Jeff worked in the operating room with neurosurgeons and orthopedic surgeons, selling and providing service on Medtronic spinal implants and image-guided surgery equipment. Prior to this role, Jeff devoted two years to pursuing a career as a professional quarterback, spending time with the Kansas City Chiefs and Dallas Cowboys. Since joining Hatteras, Jeff has worked in a corporate development role in a medical device portfolio company, and assisted in overall firm operations, deal flow activities and diligence. Jeff focuses primarily on Hatteras’ medical device and healthcare IT efforts, as well as assists in the execution of Hatteras’ VCMF mandate.

    Jeff holds a bachelor’s degree from Princeton University, and an MBA from Duke University, with a focus on healthcare and finance.

    Community and Board Engagements:

    Jeff is a board observer at Wildflower Health, NurseGrid, NeuroTronik, ORIG3N, Qvella, Contego Medical, Medfusion and Jumo Health. He has served on the Oversight Committee for the National Football League’s Head Health Tech Challenge, the Board of Directors of the Council for Entrepreneurial Development in Durham, and various panels for the North Carolina Biotech Center and SE BIO.

  • Ben Scruggs, PhD


    Ben Scruggs

    Prior to joining Hatteras in 2016, Ben completed a postdoctoral fellowship in the Epigenetics and Stem Cell Biology Laboratory at the National Institute of Environmental Health Sciences. He has performed research in the fields of genomics, metabolism, RNA biology, and transcription regulation. His research has been published in peer-reviewed journals including Molecular Cell and Cell Metabolism, among others. Ben focuses on the firm’s deal flow process and due diligence.

    Ben received his B.E. in biomedical engineering from Vanderbilt University and a Ph.D. in molecular cell biology from Washington University in St. Louis.

    Community and Board Engagements:

    Ben is a board observer at Graybug Vision and Trefoil Therapeutics. He serves on NHLBI’s national network of mentors and the North Carolina Microbiome Consortium Steering Committee. He has served on various committees and panels for the Council for Entrepreneurial Development, SE BIO, and SC BIO.